Clinical Trial Update: The Use of Daclizumab and Anti-Thymocyte Globulin in Lung Transplantation [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/Phase 3 trial evaluating daclizumab and anti-thymocyte globulin in lung transplantation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Transplantation

Drugs mentioned

• Daclizumab (daclizumab)
• anti-thymocyte globulin (antithymocyte globulin)

Snippet

Sponsor: Johns Hopkins University | Conditions: Patients Active and Listed for Lung Transplantation | Phase 2, Phase 3 | Status: COMPLETED